News

Gilead’s treatments for chronic hepatitis C virus (HCV) will be launched in the US, through a newly created subsidiary, Asegua Therapeutics. The authorized generics will launch at a

Also known as radiation sickness or radiation toxicity, acute radiation syndrome is a potentially life-threatening condition, caused by exposure to high radiation levels following a nuclear accident or

The acquisition of NextWave will allow Tris Pharma to expand its products for the treatment of patients with attention deficit hyperactivity disorder (ADHD). ADHD is a common neurodevelopmental

Durvalumab reduced the risk of death by 32% in comparison to standard of care in the late-stage trial. In the durvalumab arm, the median time to death or

Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade

Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year

Symbiosis recently hosted a successful inspection by the FDA for the aseptic manufacture of viral vector products for commercial supply into the U.S market at its GMP manufacturing

The interim analysis of the phase III IMpower132 study has demonstrated that Tecentriq and chemotherapy reduced the risk of disease worsening or death (progression-free survival (PFS)) by 40%

The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic receptor antagonist (LAMA) and long-acting β2-agonist